Table 4.

Biochemical remission rates achieved using long-acting SSAs as both primary and secondary therapy

Authors,Ref. Year	% of Patients Achieving GH Criteria for Remission	% of Patients with Normalized IGF-I	% of Patients Achieving Both GH Criteria for Remission and Normalized IGF-I
Octreotide LAR
Lancranjan and Atkinson,75 1999	69.8a	63.1	NR
Chanson et al,76 2000	68a	NR	65
Colao et al,77 2001	69.4a	61.1	NR
Ayuk et al,78 2002	36b	67	NR
Ayuk et al,40 2004	70b	72	NR
Alexopoulou et al,79 2004	64a	52	NR
Jallad et al,80 2005	74a	41	NR
Grottoli et al,81 2005	64a	35.7	28.6
Trepp et al,82 2005	NRa	NR	65
Cozzi et al,83 2006	68.7a	70.1	56.7
Colao et al,84 2006	NRa	NR	55.9
Ronchi et al,85 2007	43a	35	NR
Maiza et al,86 2007	70b	67	58
Mercado et al,87 2007	42a	34	25
Colao et al,88 2007	86a	84	80
Auriemma et al,89 2008	77.7a,b	62.9	62.9
Colao et al,90 2009	NRa	NR	27.5
Baldys-Waligorska et al,91 2009	63a,b	54.5	NR
Oki et al,92 2009	56.7a	53.3	36.7
Luque-Ramirez et al,93 2010	54a	46	NR
Tutuncu et al,39 2011	67c	67	63.9
Karaca et al,26 2011	45c	27	27
Octreotide LAR (nonweighted mean ± SD)	63 ± 13	55 ± 15	50 ± 19
Lanreotide Autogel
Caron et al,94 2002	NRa	NR	39
Alexopoulou et al,79 2004	48a	52	NR
Caron et al,45 2004	68a	NR	43
Caron et al,95 2006	77a	54	46
Lucas and Astorga,96 2006	54a	56	40
Ronchi et al,85 2007	62a	43	NR
Chanson et al,97 2008	85a	43	38
Melmed et al,98 2010	49a	54	38
Lombardi et al,99 2009	63a	37	NR
Attanasio et al,100 2008	42a	54	38
Salvatori et al,52 2010	76.9c	84.8	73.1
Tutuncu et al,39 2011	78.1c	78.1	78.1
Schopohl et al,101 2011	71.4b	62.9	NR
Lanreotide Autogel (nonweighted mean ± SD)	65 ± 14	56 ± 14	48 ± 16
Both long-acting SSAs (nonweighted mean ± SD)	63 ± 13	56 ± 15	49 ± 17

Abbreviation: NR, not reported.

^aGH_r <2.5 μg/L.

^bGH_r <2 μg/L.

^cGH_n <1 μg/L.